I-Mab Strengthens Senior Executive Team with New Chief Financial Officer and Chief Strategy Officer AppointmentsPRNewsWire • 11/01/21
I-Mab Announces Strategic Partnership with Sinopharm in Preparation for Launch of its Innovative Assets in ChinaPRNewsWire • 10/26/21
I-Mab Announces IND Approval for Phase 2 Clinical Trial of Efineptakin Alfa in Combination with PD-1 Therapy in ChinaPRNewsWire • 10/18/21
I-Mab Advances Late-stage Development of Its Differentiated CD38 Antibody Felzartamab (TJ202) in ChinaPRNewsWire • 10/13/21
I-Mab and ABL Bio to Present Preclinical Data of TJ-CD4B/ABL111 and TJ-L14B/ABL503 at the 2021 SITC Annual MeetingPRNewsWire • 10/05/21
I-Mab Reports Multiple Positive Clinical Updates of Differentiated CD47 Antibody LemzoparlimabPRNewsWire • 09/30/21
I-Mab Announces Acceptance of IND Application from China NMPA for Phase 2 Clinical Trial of Enoblituzumab in Combination with Pembrolizumab in Solid TumorsPRNewsWire • 09/28/21
I-Mab (IMAB) CEO Joan Huaqiong Shen on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/31/21
I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Six Months Ended June 30, 2021PRNewsWire • 08/31/21
I-Mab to Provide Business and Corporate Updates and Report Financial Results for the Six Months Ended June 30, 2021 on August 31, 2021PRNewsWire • 08/17/21
I-Mab Stock Is Trading Lower After Unveiling Mid-Stage Trial Data Of Plonmarlimab In Hospitalized COVID-19 PatientsBenzinga • 08/11/21
I-Mab Reports Positive Interim Analysis from Phase 2/3 Study of its GM-CSF Antibody Plonmarlimab (TJM2) to Treat Patients with Severe COVID-19PRNewsWire • 08/11/21
I-Mab Announces IND Approval by FDA to Initiate Phase 1 Study for Protollin for the Treatment of Alzheimer's DiseasePRNewsWire • 07/30/21
I-Mab Announces Authorization of a Renewed Stock Repurchase Program by the Company up to US$40 MillionPRNewsWire • 07/29/21
I-Mab Stock Moves Higher As IND For Mid-Stage Efineptakin Cancer Trial Accepted By ChinaBenzinga • 07/28/21
I-Mab Announces IND Acceptance for Phase 2 Clinical Trial of Efineptakin Alfa in Combination with PD-1 Therapy in ChinaPRNewsWire • 07/28/21